157 related articles for article (PubMed ID: 21069410)
21. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
22. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
23. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
[TBL] [Abstract][Full Text] [Related]
24. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
25. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
26. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
28. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF
Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
[TBL] [Abstract][Full Text] [Related]
30. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
[TBL] [Abstract][Full Text] [Related]
31. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
Khedr NF; El-Ashmawy NE; El-Bahrawy HA; Haggag AA; El-Abd EE
Fundam Clin Pharmacol; 2013 Oct; 27(5):526-34. PubMed ID: 22762129
[TBL] [Abstract][Full Text] [Related]
32. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
[TBL] [Abstract][Full Text] [Related]
33. Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes.
Mori H; Okada Y; Kishikawa H; Inokuchi N; Sugimoto H; Tanaka Y
J Bone Miner Metab; 2013 Jan; 31(1):89-95. PubMed ID: 22868657
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
Prestwood KM; Gunness M; Muchmore DB; Lu Y; Wong M; Raisz LG
J Clin Endocrinol Metab; 2000 Jun; 85(6):2197-202. PubMed ID: 10852452
[TBL] [Abstract][Full Text] [Related]
36. The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency.
Zirilli L; Maffei L; Meunier PJ; Chavassieux P; Carani C; Rochira V
Bone; 2009 Nov; 45(5):827-32. PubMed ID: 19345749
[TBL] [Abstract][Full Text] [Related]
37. Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.
Kimura S; Saito M; Kida Y; Seki A; Isaka Y; Marumo K
Osteoporos Int; 2017 Mar; 28(3):1109-1119. PubMed ID: 27796444
[TBL] [Abstract][Full Text] [Related]
38. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
39. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
[TBL] [Abstract][Full Text] [Related]
40. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
